



Cancer Prevention and Control CIRB Meeting Agenda

May 28, 2026

I. Amendment Review

EAQ223, The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials (Version Date 03/30/26)

II. Amendment Review

INT23-14-01, Refining Tamoxifen Dose for Premenopausal Breast Cancer Risk Reduction (RENAISSANCE): A Phase II Single Arm Trial (Version Date 04/20/26)

III. Amendment Review

UMI22-09-01, Phase IIA Trial of Acolbifene (20 mg) vs Low Dose Tamoxifen (5 mg) in Pre-menopausal Women at High Risk for Development of Breast Cancer (Version Date 04/15/26)

IV. Continuing Review

A171601, A phase II trial assessing the tolerability of palbociclib in combination with letrozole or fulvestrant in patients aged 70 and older with estrogen receptor-positive, HER2-negative metastatic breast cancer (Version Date 01/23/26)

V. Continuing Review

A221801, The Revitalize Trial: Reducing Vaginal Atrophy with Fractional CO2 Laser for Breast Cancer Survivors (Version Date 01/26/26)

VI. Continuing Review

UMI22-09-02, Phase I Trial of ONC201 for Chemoprevention of Colorectal Cancer (Version Date 02/03/26)

VII. Continuing Review

URCC-24060, Impact of Targeted Therapy on Cancer-Related Cognitive Impairment (Version Date 07/11/25)
